UBS Group
NUVB icon

UBS Group’s Nuvation Bio NUVB Stock Holding History

UBS Group’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.34M Sell
1,116,881
-257,066
-19% -$1.26M ﹤0.01% 3912
2026
Q1 		$5.89M Buy
1,373,947
+758,545
+123% +$4.23M ﹤0.01% 3892
2025
Q4 		$5.51M Sell
615,402
-292,699
-32% -$1.81M ﹤0.01% 3925
2025
Q3 		$3.36M Buy
908,101
+434,162
+92% +$1.18M ﹤0.01% 4447
2025
Q2 		$924K Sell
473,939
-397,753
-46% -$828K ﹤0.01% 5512
2025
Q1 		$1.53M Sell
871,692
-979,001
-53% -$2.23M ﹤0.01% 4916
2024
Q4 		$4.92M Buy
1,850,693
+1,385,584
+298% +$3.57M ﹤0.01% 3869
2024
Q3 		$1.07M Buy
465,109
+65,526
+16% +$200K ﹤0.01% 4590
2024
Q2 		$1.17M Sell
399,583
-24,219
-6% -$73.9K ﹤0.01% 4274
2024
Q1 		$1.54M Buy
423,802
+42,483
+11% +$81.6K ﹤0.01% 4198
2023
Q4 		$576K Buy
381,319
+285,713
+299% +$368K ﹤0.01% 4997
2023
Q3 		$128K Buy
95,606
+285
+0.3% +$474 ﹤0.01% 5672
2023
Q2 		$172K Sell
95,321
-15,033
-14% -$25.6K ﹤0.01% 5589
2023
Q1 		$183K Buy
+110,354
New +$224K ﹤0.01% 5452
2022
Q4 		– Sell
-5,620
Closed -$13K – 11009
2022
Q3 		$13K Buy
5,620
+3,024
+116% +$8.63K ﹤0.01% 8053
2022
Q2 		$8K Buy
2,596
+2,560
+7,111% +$11.2K ﹤0.01% 8327
2022
Q1 		$0 Sell
36
-473
-93% -$2.66K ﹤0.01% 10693
2021
Q4 		$4K Buy
509
+422
+485% +$3.88K ﹤0.01% 9534
2021
Q3 		$1K Buy
87
+20
+30% +$181 ﹤0.01% 9214
2021
Q2 		$1K Sell
67
-1,996
-97% -$22.8K ﹤0.01% 9171
2021
Q1 		$22K Sell
2,063
-769
-27% -$8.6K ﹤0.01% 7293
2020
Q4 		$33K Buy
+2,832
New +$29.5K ﹤0.01% 6558

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

UBS Group's NUVB Position: Q2 2026 in Review

UBS Group reduced its Nuvation Bio (NUVB) stake by 19% in Q2 2026, selling an estimated $1.26M and leaving 1,116,881 shares worth $6.34M. The position accounts for ﹤0.01% of the portfolio, ranked #3912.

UBS Group first reported a position in NUVB in Q4 2020 and has held it in 22 quarters since. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • UBS Group held 1,116,881 shares of Nuvation Bio worth $6.34M as of Q2 2026.
  • UBS Group sold 257,066 Nuvation Bio shares in Q2 2026, an estimated $1.26M.
  • Nuvation Bio made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #3912 holding.
  • UBS Group first reported a position in Nuvation Bio in Q4 2020 and has held it in 22 quarters since.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.